Abstract:Triple-negative breast cancer (TNBC) represents the most aggressive subtype of breast cancer, and the therapeutic options available for TNBC are limited. In addition to surgery and chemotherapy, radiotherapy (RT) is a primary treatment modality for TNBC. However, radio-resistance poses significant challenges to TNBC treatment. Prior research has shown that losartan, an angiotensin receptor blocker, can improve vessel perfusion and drug delivery, thereby enhancing the efficacy of chemotherapy or radiotherapy in cancer. However, in our study, we found that losartan could enhance the radiosensitivity of TNBC in immunocompetent mice model, but not in immunodeficient mice model and TNBC cells. It suggested that losartan might enhance the radiosensitivity of TNBC in an immune system dependent way. Previous studies had noted that tumor immune microenvironment (TIME) played an important role in radio-resistance. Therefore, we focused on the TIME in our further study. For immune cells, it had reported that the recruitment and activation of immunosuppressive cells such as M2 phenotype tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), could lead to the establishment of and immunosuppressive TIME and decreased the radiosensitivity. In this study, we found losartan facilitated the polarization of TAMs towards the M1 phenotype, and impeded the immunosuppressive function of MDSCs after RT in 4T1 TNBC mice model. Additionally, losartan also caused a significant increase of CD8+ T lymphocytes in the TIME, and also markedly enhanced the activity of infiltrated T cell. When the CD8+ T cells were eliminated by anti-CD8α antibody, the radiosensitization effect of losartan was significantly decreased. Therefore, T-cell mediated tumor suppression is essential for the radiosensitization caused by losartan in TNBC. For immune factors, we found that TNBC exhibited an increase in the expression of programmed death-ligand (PD-L1) and indoleamine-2,3-dioxygenase (IDO) upon exposure to irradiation, and the combination of losartan resulted in a significant reduction in their expression in vitro and in vivo. At the same time, the 4T1 TNBC transplantation tumors were significantly inhibited by losartan combined with PD-1 inhibitor after RT, which indicated that losartan might amplify the efficacy of radio-immunotherapy. Collectively, these findings suggest that losartan could reshape the TIME of TNBC through regulating immune cells (TAMs, MDCSs and CD8+ T cells) and immune factors (PD-L1 and IDO), which result in the enhancement of radiosensitivity of TNBC. In our investigation, losartan was innovatively found to increase the radiosensitivity of TNBC by reshaping the TIME rather than on the tumor stroma. As one of the most commonly prescribed drugs for hypertension, the safety and affordability of losartan have been extensively confirmed. In the future, losartan combined with radiotherapy might be a promising strategy for TNBC treatment. Citation Format: Cuiwei Liu, Xu Wang, Zihan Xia, Yuxi Ma, Yanxia Zhao. Losartan enhances the radiosensitivity of triple-negative breast cancer by reshaping the tumor immune microenvironment [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr PO3-24-10.

Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models

Co-Inhibition Of Glut-1 Expression And The Pi3k/Akt Signaling Pathway To Enhance The Radiosensitivity Of Laryngeal Carcinoma Xenografts In Vivo

Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis

Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model

Zoledronic Acid Inhibits TSC2-null Cell Tumor Growth Via RhoA/YAP Signaling Pathway in Mouse Models of Lymphangioleiomyomatosis.

Whole-Brain Radiotherapy Combined with Anlotinib for Multiple Brain Metastases from Non-small Cell Lung Cancer Without Targetable Driver Mutation: A Single-Arm, Phase II Study

Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma

Epigenetic reprogramming shapes the cellular landscape of schwannoma

Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK

Abstract A104: Losartan rewires ovarian cancer tumor-immune microenvironment and suppresses IGF-1 to amplify chemo-immunotherapy sensitivity

Abstract PO3-24-10: Losartan enhances the radiosensitivity of triple-negative breast cancer by reshaping the tumor immune microenvironment

Improved Tumor Control Following Radiosensitization with Ultrasound-Sensitive Oxygen Microbubbles and Tumor Mitochondrial Respiration Inhibitors in a Preclinical Model of Head and Neck Cancer

A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma

EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma

Losartan-based nanocomposite hydrogel overcomes chemo-immunotherapy resistance by remodeling tumor mechanical microenvironment

Addition of losartan to FOLFORINOX and chemoradiation downregulates pro-invasion and immunosuppression-associated genes in locally advanced pancreatic cancer

Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma

Novel Patient-Derived Xenograft and Cell Line Models for Therapeutic Screening in NF2-associated Schwannoma.

Canertinib induces ototoxicity in three preclinical models

Tumors of the nervous system and hearing loss: beyond vestibular schwannomas

Candesartan induces tumor vascular normalization to improve the efficacy of radiotherapy in the therapeutic window